

BONESUPPORT - Leading an ongoing paradigm shift

Redeye revisits its market share assumptions for BONESUPPORT's extremities business. We argue that the company's products are likely to be strong contenders to the standard of care, opting for increased market share assumptions, rendering an updated fair value range. In the near term, we identify several key catalysts to support the strong share price momentum.

Read more and download the Research Update.

Follow companies at Redeye to receive the latest equity research within Life Science and Technology.

This is a press release from Redeye - Research Powered Investment Banking. www.redeye.se/

Attachments

BONESUPPORT - Leading an ongoing paradigm shift